[2',5'-BIS-O-(TERT-BUTYLDIMETHYLSILYL)]-3'-SPIRO-5''-(4''-AMINO-1'',2''-OXATHIOLE-2'',2''-DIOXIDE) (TSAO) DERIVATIVES OF PURINE AND PYRIMIDINE NUCLEOSIDES AS POTENT AND SELECTIVE INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1

被引:69
作者
BALZARINI, J [1 ]
PEREZPEREZ, MJ [1 ]
SANFELIX, A [1 ]
VELAZQUEZ, S [1 ]
CAMARASA, MJ [1 ]
DECLERCQ, E [1 ]
机构
[1] INST QUIM MED,E-28006 MADRID,SPAIN
关键词
D O I
10.1128/AAC.36.5.1073
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The [2',5'-bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) derivatives of ribofuranosylthymine, uridine, 5-bromouridine, 5-methylcytidine, inosine, and adenosine are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) but not of other retroviruses (HIV-2, simian immunodeficiency virus, or Moloney murine sarcoma virus). The 50% effective concentration (EC50) of the most active TSAO congeners for inhibition of HIV-1 replication ranged from 0.034 to 0.44-mu-g/ml. The 50% cytotoxic concentration (CC50) affecting the viability of MT-4 cells ranged from 2.35 to 18-mu-g/ml. The TSAO thymine derivative proved to be a highly selective inhibitor of HIV-1 reverse transcriptase but not of HIV-2 reverse transcriptase and DNA polymerase-alpha. Introduction of an alkyl or alkenyl function at N3 of the thymine ring markedly decreased cytotoxicity but did not affect the antiviral activity of the compounds. The most potent (EC50, 0.034-mu-g/ml) and most selective (CC50/EC50, 4088) inhibitor of HIV-1 replication proved to be the N3-methyl derivative of {1-[2',5'-bis-O-(tert-butyldimethylsilyl)beta-D-ribofuranosyl]thymine}-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide). This compound should be considered as a promising drug candidate for the treatment of HIV-1 infections.
引用
收藏
页码:1073 / 1080
页数:8
相关论文
共 32 条
[1]  
BABA M, 1991, MOL PHARMACOL, V39, P805
[2]   POTENT AND SELECTIVE-INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) BY 5-ETHYL-6-PHENYLTHIOURACIL DERIVATIVES THROUGH THEIR INTERACTION WITH THE HIV-1 REVERSE-TRANSCRIPTASE [J].
BABA, M ;
DECLERCQ, E ;
TANAKA, H ;
UBASAWA, M ;
TAKASHIMA, H ;
SEKIYA, K ;
NITTA, I ;
UMEZU, K ;
NAKASHIMA, H ;
MORI, S ;
SHIGETA, S ;
WALKER, RT ;
MIYASAKA, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) :2356-2360
[3]   ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVITIES AND PHARMACOKINETICS OF NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVES [J].
BABA, M ;
DECLERCO, E ;
IIDA, S ;
TANAKA, H ;
NITTA, I ;
UBASAWA, M ;
TAKASHIMA, H ;
SEKIYA, K ;
UMEZU, K ;
NAKASHIMA, H ;
SHIGETA, S ;
WALKER, RT ;
MIYASAKA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2358-2363
[4]   HIGHLY SPECIFIC-INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY A NOVEL 6-SUBSTITUTED ACYCLOURIDINE DERIVATIVE [J].
BABA, M ;
TANAKA, H ;
DECLERCQ, E ;
PAUWELS, R ;
BALZARINI, J ;
SCHOLS, D ;
NAKASHIMA, H ;
PERNO, CF ;
WALKER, RT ;
MIYASAKA, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (03) :1375-1381
[5]   ESTIMATION OF THE LIPOPHILICITY OF ANTI-HIV NUCLEOSIDE ANALOGS BY DETERMINATION OF THE PARTITION-COEFFICIENT AND RETENTION TIME ON A LICHROSPHER-60 RP-8 HPLC COLUMN [J].
BALZARINI, J ;
COOLS, M ;
DECLERCQ, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 158 (02) :413-422
[6]   9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) EFFECTIVELY INHIBITS RETROVIRUS REPLICATION INVITRO AND SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS-MONKEYS [J].
BALZARINI, J ;
NAESENS, L ;
SLACHMUYLDERS, J ;
NIPHUIS, H ;
ROSENBERG, I ;
HOLY, A ;
SCHELLEKENS, H ;
DECLERCQ, E .
AIDS, 1991, 5 (01) :21-28
[7]  
BALZARINI J, 1992, ARCH INT PHYS BIOCH, V100, pB28
[8]  
BALZARINI J, IN PRESS P NATL ACAD
[9]  
BALZARINI J, IN PRESS J BIOL CHEM
[10]  
CAMARASA MJ, IN PRESS J MED CHEM